1. Home
  2. ROIV vs RGEN Comparison

ROIV vs RGEN Comparison

Compare ROIV & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ROIV
  • RGEN
  • Stock Information
  • Founded
  • ROIV 2014
  • RGEN 1981
  • Country
  • ROIV United Kingdom
  • RGEN United States
  • Employees
  • ROIV N/A
  • RGEN N/A
  • Industry
  • ROIV Biotechnology: Pharmaceutical Preparations
  • RGEN Medical/Dental Instruments
  • Sector
  • ROIV Health Care
  • RGEN Health Care
  • Exchange
  • ROIV Nasdaq
  • RGEN Nasdaq
  • Market Cap
  • ROIV 8.4B
  • RGEN 8.0B
  • IPO Year
  • ROIV N/A
  • RGEN N/A
  • Fundamental
  • Price
  • ROIV $10.79
  • RGEN $126.50
  • Analyst Decision
  • ROIV Buy
  • RGEN Buy
  • Analyst Count
  • ROIV 4
  • RGEN 12
  • Target Price
  • ROIV $17.50
  • RGEN $172.67
  • AVG Volume (30 Days)
  • ROIV 5.9M
  • RGEN 815.5K
  • Earning Date
  • ROIV 05-29-2025
  • RGEN 04-29-2025
  • Dividend Yield
  • ROIV N/A
  • RGEN N/A
  • EPS Growth
  • ROIV N/A
  • RGEN N/A
  • EPS
  • ROIV N/A
  • RGEN N/A
  • Revenue
  • ROIV $122,585,000.00
  • RGEN $650,429,000.00
  • Revenue This Year
  • ROIV N/A
  • RGEN $13.93
  • Revenue Next Year
  • ROIV N/A
  • RGEN $14.35
  • P/E Ratio
  • ROIV N/A
  • RGEN N/A
  • Revenue Growth
  • ROIV 140.04
  • RGEN 4.88
  • 52 Week Low
  • ROIV $8.73
  • RGEN $102.97
  • 52 Week High
  • ROIV $13.06
  • RGEN $182.52
  • Technical
  • Relative Strength Index (RSI)
  • ROIV 50.06
  • RGEN 44.61
  • Support Level
  • ROIV $10.58
  • RGEN $123.10
  • Resistance Level
  • ROIV $11.77
  • RGEN $135.47
  • Average True Range (ATR)
  • ROIV 0.34
  • RGEN 6.98
  • MACD
  • ROIV -0.07
  • RGEN -0.97
  • Stochastic Oscillator
  • ROIV 17.65
  • RGEN 25.20

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: